Wolverine Trading’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $469K | Buy |
17,900
+7,200
| +67% | +$167K | ﹤0.01% | 3786 |
|
|
2025
Q2 | $217K | Buy |
+10,700
| New | +$208K | ﹤0.01% | 3825 |
|
|
2025
Q1 | – | Sell |
-10,200
| Closed | -$256K | – | 4849 |
|
|
2024
Q4 | $256K | Sell |
10,200
-2,900
| -22% | -$78.8K | ﹤0.01% | 4207 |
|
|
2024
Q3 | $435K | Buy |
+13,100
| New | +$499K | ﹤0.01% | 3202 |
|
|
2023
Q2 | – | Sell |
-8,800
| Closed | -$313K | – | 4312 |
|
|
2023
Q1 | $313K | Buy |
8,800
+3,000
| +52% | +$129K | ﹤0.01% | 2973 |
|
|
2022
Q4 | $259K | Buy |
+5,800
| New | +$207K | ﹤0.01% | 2910 |
|
|
2022
Q3 | – | Sell |
-32,300
| Closed | -$899K | – | 4673 |
|
|
2022
Q2 | $899K | Buy |
32,300
+16,800
| +108% | +$488K | ﹤0.01% | 2017 |
|
|
2022
Q1 | $536K | Buy |
15,500
+3,500
| +29% | +$112K | ﹤0.01% | 3139 |
|
|
2021
Q4 | $467K | Buy |
12,000
+6,200
| +107% | +$270K | ﹤0.01% | 3544 |
|
|
2021
Q3 | $301K | Buy |
+5,800
| New | +$272K | ﹤0.01% | 4695 |
|
|
2020
Q4 | – | Sell |
-23,000
| Closed | -$349K | – | 4860 |
|
|
2020
Q3 | $349K | Buy |
23,000
+11,800
| +105% | +$138K | ﹤0.01% | 3208 |
|
|
2020
Q2 | $140K | Sell |
11,200
-700
| -6% | -$3.1K | ﹤0.01% | 4018 |
|
|
2020
Q1 | $21K | Buy |
+11,900
| New | +$26.9K | ﹤0.01% | 4420 |
|
|
2019
Q4 | – | Sell |
-21,500
| Closed | -$47K | – | 4703 |
|
|
2019
Q3 | $47K | Buy |
21,500
+2,800
| +15% | +$6.48K | ﹤0.01% | 4057 |
|
|
2019
Q2 | $50K | Sell |
18,700
-5,100
| -21% | -$17.3K | ﹤0.01% | 4192 |
|
|
2019
Q1 | $117K | Buy |
+23,800
| New | +$125K | ﹤0.01% | 4077 |
|
|
2018
Q4 | – | Sell |
-1,147
| Closed | -$8K | – | 4520 |
|
|
2018
Q3 | $8K | Buy |
+1,147
| New | +$8.03K | ﹤0.01% | 4815 |
|
|
2018
Q1 | – | Sell |
-2,800
| Closed | -$119K | – | 5143 |
|
|
2017
Q4 | $119K | Sell |
2,800
-1,253
| -31% | -$53.7K | ﹤0.01% | 4398 |
|
|
2017
Q3 | $174K | Buy |
4,053
+1,666
| +70% | +$62.5K | ﹤0.01% | 3881 |
|
|
2017
Q2 | $90K | Sell |
2,387
-2,400
| -50% | -$106K | ﹤0.01% | 3921 |
|
|
2017
Q1 | $258K | Buy |
4,787
+1,400
| +41% | +$72.9K | ﹤0.01% | 3208 |
|
|
2016
Q4 | $180K | Buy |
+3,387
| New | +$193K | ﹤0.01% | 3819 |
|
|
2016
Q3 | – | Sell |
-4,260
| Closed | -$282K | – | 4631 |
|
|
2016
Q2 | $282K | Buy |
+4,260
| New | +$270K | ﹤0.01% | 2866 |
|
Other funds holding CLDX
KCM
BG
CC
Wolverine Trading's CLDX Position: Q1 2024 in Review
Wolverine Trading sold out of Celldex Therapeutics (CLDX) in Q1 2024, closing a stake of 5,058 shares — an estimated $201K sold.
Wolverine Trading first reported a position in CLDX in Q4 2016 and held it in 8 quarters. The position peaked at $201K in Q4 2023. 197 funds tracked by Wall St. Rank hold CLDX as of Q1 2024.
- Wolverine Trading reported no remaining Celldex Therapeutics position as of Q1 2024 after selling out during the quarter.
- Wolverine Trading sold 5,058 Celldex Therapeutics shares in Q1 2024, an estimated $201K.
- Wolverine Trading first reported a position in Celldex Therapeutics in Q4 2016 and held it in 8 quarters.
- Wolverine Trading's Celldex Therapeutics position peaked at $201K in Q4 2023.
- 197 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2024.
Based on Wolverine Trading's 13F filing for Q1 2024, filed 15 May 2024.